<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03124576</url>
  </required_header>
  <id_info>
    <org_study_id>NL56796.068.16</org_study_id>
    <nct_id>NCT03124576</nct_id>
  </id_info>
  <brief_title>Reappraisal of Atrial Fibrillation: RACE V - Work Package 5</brief_title>
  <acronym>RACE V- WP 5</acronym>
  <official_title>Reappraisal of Atrial Fibrillation: Interaction Between HyperCoagulability, Electrical Remodeling, and Vascular Destabilisation in the Progression of AF- Closing the Translational Gap</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Academisch Ziekenhuis Maastricht</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Academisch Ziekenhuis Maastricht</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In the proposed study the investigators aim to clarify the relative contribution of these
      different mechanisms to the progression of AF. Also the contribution of the individual
      genetic background will be investigated. Furthermore, the investigators aim to identify
      clinical parameters and biomarkers informing on the main mechanisms of AF progression in
      atrial tissue.

      For this purpose, in all included patients atrial biopsies will be taken during cardiac
      surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An estimated 380 patients will be included

      Four patient categories will be included enabling to study patients with different stages of
      AF progression;

        1. Patients without history of atrial fibrillation, without new onset atrial fibrillation
           detected by continuous rhythm monitoring after surgery (control group),

        2. Patients without history of atrial fibrillation, with new onset atrial fibrillation
           detected by continuous rhythm monitoring,

        3. Patients with self-terminating atrial fibrillation at inclusion, and

        4. Patients with non-self-terminating atrial fibrillation at inclusion. At baseline
           in-depth phenotyping and genotyping will be performed. Continuous rhythm monitoring will
           also be performed in all patients. The combination of extensive phenotyping, genotyping
           and atrial fibrillation burden follow-up offers the unique opportunity to study the
           atrial tissue alterations and atrial gene expression changes in different stages of
           atrial fibrillation progression and to correlate these data to the phenotype of the
           patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Biochemical factors in atrial biopsies and blood samples associated with atrial fibrillation and contributing to atrial fibrillation progression</measure>
    <time_frame>2.5 year follow up</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Molecular factors in atrial biopsies and blood samples associated with atrial fibrillation and contributing to atrial fibrillation progression</measure>
    <time_frame>2.5 year follow up</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Genetic factors in atrial biopsies and blood samples associated with atrial fibrillation and contributing to atrial fibrillation progression</measure>
    <time_frame>2.5 year follow up</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>atrial fibrillation burden</measure>
    <time_frame>2.5 year follow up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of atrial fibrillation episodes</measure>
    <time_frame>2.5 year follow up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of atrial fibrillation episodes</measure>
    <time_frame>2.5 year follow up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major adverse cardiovascular and cerebrovascular events (i.e. death, stroke, myocardial infarction)</measure>
    <time_frame>2.5 year follow up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>First recurrent atrial fibrillation;</measure>
    <time_frame>2.5 year follow up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self-terminating atrial fibrillation turning into non-self-terminating atrial fibrillation measured from ECGs and implantable loop recorders</measure>
    <time_frame>2.5 year follow up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrical atrial fibrillation complexity or signs of atrial conduction disturbances measured from ECGs</measure>
    <time_frame>2.5 year follow up</time_frame>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">380</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <description>Without history of atrial fibrillation/without newly developed atrial fibrillation detected by continuous rhythm monitoring with a an Implantable loop recorder</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group B</arm_group_label>
    <description>Patients without history of atrial fibrillation, with new onset atrial fibrillation detected by continuous rhythm monitoring with a an Implantable loop recorder</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group C</arm_group_label>
    <description>Patients with self-terminating atrial fibrillation at inclusion Implantable loop recorder is used for continuous rhythm monitoring</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group D</arm_group_label>
    <description>Patients with non-self-terminating atrial fibrillation at inclusion Implantable loop recorder is used for continuous rhythm monitoring</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Implantable loop recorder</intervention_name>
    <description>Continuous rhythm monitoring Medtronic</description>
    <arm_group_label>control group</arm_group_label>
    <arm_group_label>group B</arm_group_label>
    <arm_group_label>group C</arm_group_label>
    <arm_group_label>group D</arm_group_label>
    <other_name>Reveal LINQ™,Medtronic</other_name>
    <other_name>ConfirmTM, St. Jude</other_name>
    <other_name>BiomonitorTM, Biotronik</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      atrial tissue samples, whole blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        380 patiënts undergoing elective open chest heart surgery.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 years;

          -  Undergoing first elective open chest cardiac surgery or surgical ablation for atrial
             fibrillation;

          -  Able and willing to sign informed consent for the registry;

          -  Able and willing to undergo implantation of implantable loop recorder (unless the
             patients has a pacemaker or ICD with atrial leads)

        Exclusion Criteria:

          -  • Deemed unsuitable or not willing to undergo implantation of implantable loop
             recorder or attend follow-up visits.

               -  Pregnancy.

               -  Life expectancy of less than 2.5 years.

               -  History of prior cardiac surgery or ablation for atrial fibrillation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jos Maessen, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Academisch Ziekenhuis Maastricht</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Martijn Gilbers, Drs.</last_name>
    <phone>0031620606559</phone>
    <email>M.Gilbers@maastrichtuniversity.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>AZMaastricht</name>
      <address>
        <city>Maastricht</city>
        <state>Limburg</state>
        <zip>6229 HX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martijn Gilbers, Drs</last_name>
      <phone>0031620606559</phone>
      <email>martijn.gilbers@mumc.nl</email>
    </contact>
    <contact_backup>
      <last_name>Elham Bidar, Drs</last_name>
      <phone>0031624266586</phone>
      <email>elham.bidar@mumc.nl</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 2016</study_first_submitted>
  <study_first_submitted_qc>April 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 24, 2017</study_first_posted>
  <last_update_submitted>April 18, 2017</last_update_submitted>
  <last_update_submitted_qc>April 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Academisch Ziekenhuis Maastricht</investigator_affiliation>
    <investigator_full_name>J. G. Maessen</investigator_full_name>
    <investigator_title>Prof. Dr.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

